← Eichor
Study identifier: NCT07416461 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease

Condition: Invasive Non-Typhoidal Salmonella Disease · Malaria · Malaria Vaccine  ·  Sponsor: International Vaccine Institute

PhaseN/A
Planned participants10000
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to learn about the impact of malaria vaccination on the risk of invasive non-typhoidal Salmonella disease in children below the age of 5. Eligible participants residing in the Kisantu Health Zone (DRC) and presenting fever are enrolled in healthcare facilities and tested for malaria and iNTS. Using a case-control (test-negative) design, the researchers will look at the malaria vaccination status of participants with and without iNTS infection to determine if the malaria vaccine protects against iNTS.

This description comes directly from the study's public registry record.

Talk to the study team

Birkneh Tadesse, MD, PHD  ·  +821098041348  ·  Birkneh.Tadesse@ivi.int

Camille Dauvergne, PharmD, M.S.c  ·  +821091480309  ·  Camille.Dauvergne@ivi.int

Always discuss trial participation with your own doctor first.

Locations (1)

Institut National de Recherche Biomedicale (INRB)Kinshasa, Democratic Republic of the CongoRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07416461